<DOC>
	<DOCNO>NCT01091831</DOCNO>
	<brief_summary>This multicenter , randomize , open label study design compare efficacy safety lenalidomide low-dose alkylating agent versus high-dose melphalan follow stem cell support newly diagnose symptomatic MM patient 65 year age young .</brief_summary>
	<brief_title>Cyclophosphamide , Lenalidomide Dexamethasone ( CRD ) Versus Melphalan ( 200 mg/m2 ) Followed By Autologous Stem Cell Transplant ( ASCT ) In Newly Diagnosed Multiple Myeloma Subjects</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient , investigator ( ) opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Patient 65 year old young time signing informed consent Women childbearing potential must agree use 2 method contraception : 1 effective ( example hormonal tubal ligation ) 1 barrier ( example latex condom , diaphragm ) least 4 week start therapy , Treatment Period , 4 week last dose lenalidomide Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) study drug therapy ( include dose interruption ) 4 week discontinuation lenalidomide therapy . Negative serum betahuman chorionic gonadotropin ( betaHCG ) pregnancy test 24 hour prior begin therapy 4 week interval woman regular menstrual cycle every 2 week woman irregular menstrual cycle study treatment subject childbearing potential Patient diagnose symptomatic multiple myeloma base standard criterion ( 10 ) , measurable disease , define follow : quantifiable serum monoclonal protein value ( generally , necessarily , great 1 g/dL IgG MProtein great 0.5 g/dL IgA MProtein ) , applicable , urine lightchain excretion &gt; 200 mg/24 hour ; measurable plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( i.e . MRI , CTScan ) ; bone marrow plasma cell &gt; 10 % . Patient Karnofsky performance status ≥ 60 % . Patient lifeexpectancy &gt; 6 month Patient HBV , HCV HIV negative test . Patients must normal ECG NYHA ≤ 2 ; evaluation ejection fraction ECHO MUGA optional Patients must normal chest X ray ; evaluation pulmonary function study mechanical aspect ( FEV1 , FVC , etc ) diffusion capacity ( DLCO ) optional . Patient follow laboratory value within 14 day Baseline ( day 1 Cycle 1 ) : Platelet count ≥ 75 x 109/L without transfusion support within 7 day test . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L without use growth factor . Corrected serum calcium ≤ 14 mg/dL ( 3.5 mmol/L ) . Aspartate transaminase ( AST ) : ≤ 2.5 x upper limit normal ( ULN ) . Alanine transaminase ( ALT ) : ≤ 2.5 x ULN . Total bilirubin : ≤ 1.5 x ULN . Calculated measured creatinine clearance : ≥ 20 mL/minute Patient baseline bone marrow sample available cytogenetics , process eventually centralize . Previous treatment antimyeloma therapy ( include radiotherapy , bisphosphonates , single short course steroid ; &lt; equivalent dexamethasone 40 mg/day 4 day ) . Any serious medical condition , include presence laboratory abnormality , place subject unacceptable risk participates study confounds experimental ability interpret data study . Pregnant lactate woman . A serum βhCG pregnancy test must perform Screening visit , female patient childbearing potential . If test positive , patient must exclude study . Confirmation patient pregnant must establish negative serum urinary pregnancy test result obtain 1 day prior Baseline visit ( day visit result available drug delivery ) . A pregnancy test require naturally postmenopausal woman ( menses time precede 24 consecutive month ) surgically sterilise woman ( hysterectomy , bilateral ovariectomy , bilateral salpingectomy ) ; Prior history malignancy , multiple myeloma , unless subject free disease ≥ 3 year . Exceptions include follow : basal cell carcinoma skin , squamous cell carcinoma skin , carcinoma situ cervix , carcinoma situ breast , incidental histologic find prostate cancer ( TNM stage T1a T1b ) Patients previously diagnose bearing deep venous thrombosis arterial thromboembolic event within late 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>High dose melphalan</keyword>
	<keyword>Mobilization</keyword>
	<keyword>CD 34</keyword>
	<keyword>Newly Diagnosed patient</keyword>
</DOC>